QPPV.COM KNOWLEDGE ASSESSMENT

Epcoritamab: Mechanism, Clinical Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Epcoritamab: Mechanism, Clinical Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the primary inspection-readiness principle for epcoritamab safety surveillance?

Demonstrate traceability from the original report through follow-up, medical review, signal evaluation and governance decisions Demonstrate that every report received the same follow-up questions Demonstrate only that product information was available to staff Demonstrate that all uncertain diagnoses were converted into definitive categories

Question 2 of 10 Why should spontaneous-reporting patterns not be interpreted as direct estimates of epcoritamab incidence?

Spontaneous reports are unaffected by awareness or monitoring intensity Reporting is influenced by awareness, indication, monitoring, treatment setting and reporting behaviour, among other factors Spontaneous reports contain laboratory data for every exposed patient Incidence can be calculated accurately from any sufficiently large spontaneous-report database

Question 3 of 10 A report describes a patient as having 'possible ICANS' because of headache and confusion, but contains no examination or clinician assessment. What is the most appropriate PV approach?

Accept ICANS as confirmed because the symptoms are compatible Reject the report because neurological events cannot be assessed retrospectively Record the reported symptoms and seek clinical characterisation rather than treating the label as a confirmed diagnosis Reclassify the event as CRS because neurological events overlap with CRS

Question 4 of 10 What is the main risk of combining CRS, neurological events, infections and cytopenias into one broad aggregate category?

It makes the database technically incapable of storing any case It can obscure different mechanisms, time courses, case definitions and follow-up needs It guarantees that all cases will be considered unrelated to treatment It prevents assessment of seriousness but improves causality assessment

Question 5 of 10 Which aggregate-review strategy is most appropriate for suspected CRS?

Pool all fevers regardless of treatment stage or clinical features Examine treatment step, time to onset, severity, recurrence and management while retaining case-level clinical detail Exclude cases with competing causes because they cannot contribute to signal detection Use only spontaneous-report counts to estimate incidence

Question 6 of 10 Why is treatment-step information particularly important when assessing an acute event after epcoritamab administration?

The treatment step can help contextualise exposure intensity, timing and the likelihood of an acute pharmacological reaction Treatment step is needed only to determine whether the patient had an infection Treatment step replaces the need to document the event phenotype Treatment step determines whether a reported event is automatically serious

Question 7 of 10 Why should a neurological event after epcoritamab be documented separately from a general category of immune toxicity?

Neurological events have distinct clinical phenotypes, investigations and management considerations Neurological events cannot occur in patients with lymphoma All neurological events are necessarily unrelated to epcoritamab A separate neurological record is required only when the patient has no other adverse events

Question 8 of 10 Which statement correctly reflects the role of rechallenge in pharmacovigilance assessment?

Rechallenge should be encouraged whenever causality is uncertain Rechallenge is meaningful only if it produces the same event at the same dose Rechallenge may provide information when it occurs as part of clinical care, but it should not be encouraged solely to strengthen a PV conclusion Rechallenge is never relevant to causality assessment

Question 9 of 10 A patient develops fever several hours after an epcoritamab injection. What is the most appropriate initial pharmacovigilance interpretation?

The event should automatically be classified as CRS The event should automatically be classified as infection The fever should be clinically characterised, timed against dosing, and assessed against CRS, infection and other competing explanations The fever should be excluded because fever is an expected consequence of lymphoma

Question 10 of 10 Which mechanism most directly explains why epcoritamab can produce both antitumour activity and acute inflammatory toxicity?

It blocks a soluble inflammatory mediator without directly affecting immune cells It brings CD3-positive T cells into contact with CD20-positive B cells, promoting T-cell activation and target-cell killing It inhibits bone-marrow production of inflammatory cytokines It selectively depletes neutrophils while preserving T-cell function

QPPV.com

Epcoritamab: Mechanism, Clinical Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings